Tulmimetostat

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

LymphomaNon-Small Cell Lung CancerProstate CancerMycosis FungoidesAdvanced Solid TumorMetastatic Hormone-Sensitive Prostate Cancer (mhspc)

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

1

Velban

EEastern Cooperative Oncology Group

Preclinical

152

Tulmimetostat

Novartis

Phase 1

53

Nuvigil

NNuvo Research GmbH

Preclinical

14

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—5

Systemic Therapy

Bristol-Myers Squibb

Preclinical

16

PEG-Intron

Merck & Co.

Preclinical

17

Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

38

VP-16

FFundamenta Therapeutics, Ltd.

Preclinical

29

JY231

SShenzhen Genocury Biotech Co., Ltd.

Preclinical

110

CAR-T Therapy

UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

Preclinical

2Show 16 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer

Recruiting·VVA Office of Research and Development·Phase 1/2·NCT05467748·66 enrolled

Mycosis Fungoides1 trial

Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome

Active, not recruiting·WWashington University School of Medicine·Phase 1·NCT05944562·24 enrolled

Castrate Resistant Prostate Cancer1 trial

TulmiSTAR-01: A Two-part, Phase I Dose Escalation and Expansion Followed by a Randomized, Open-label Multicenter, Phase II Study to Assess the Safety and Efficacy of the Combination of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) vs Standard of Care in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer

Recruiting·Novartis·Preclinical·NCT07206056·188 enrolled

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)1 trial

TulmiSTAR-02: A Two-part Phase I Dose Escalation Study of Tulmimetostat (DZR123) in Combination With Darolutamide or Abiraterone Followed by Open-label, Randomized, Phase II Dose Expansion Study to Assess the Safety and Efficacy of Tulmimetostat in Combination With Darolutamide Versus Darolutamide Alone in Patients With Metastatic Hormone-sensitive Prostate Cancer

Recruiting·Novartis·Preclinical·NCT07190300·181 enrolled

Advanced Solid Tumor1 trial

A Phase 1/2 Study of DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Recruiting·Novartis·Preclinical·NCT04104776·275 enrolled

Details

Drug Info

Related News